ARGX vs. GILD, MRNA, BIIB, BNTX, NBIX, TECH, QGEN, RGEN, PCVX, and EXEL
Should you be buying argenx stock or one of its competitors? The main competitors of argenx include Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), and Exelixis (EXEL). These companies are all part of the "biological products, except diagnostic" industry.
Gilead Sciences (NASDAQ:GILD) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Gilead Sciences has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
Gilead Sciences has a net margin of 1.76% compared to Gilead Sciences' net margin of -22.58%. argenx's return on equity of 24.34% beat Gilead Sciences' return on equity.
In the previous week, Gilead Sciences had 22 more articles in the media than argenx. MarketBeat recorded 31 mentions for Gilead Sciences and 9 mentions for argenx. Gilead Sciences' average media sentiment score of 1.37 beat argenx's score of 0.89 indicating that argenx is being referred to more favorably in the news media.
Gilead Sciences has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences received 1847 more outperform votes than argenx when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 65.90% of users gave argenx an outperform vote.
83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 60.3% of argenx shares are held by institutional investors. 0.2% of Gilead Sciences shares are held by insiders. Comparatively, 2.4% of argenx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Gilead Sciences presently has a consensus target price of $83.69, indicating a potential upside of 29.35%. argenx has a consensus target price of $520.68, indicating a potential upside of 38.55%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe argenx is more favorable than Gilead Sciences.
Summary
Gilead Sciences beats argenx on 11 of the 19 factors compared between the two stocks.
Get argenx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
